The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Neuropilin‐1 expression in cancer and development
Abstract
Neuropilin (NRP)‐1 is a co‐receptor for vascular endothelial growth factor (VEGF). Preclinical data suggest that blockade of NRP1 suppresses tumour growth by inhibiting angiogenesis, in addition to directly inhibiting tumour cell proliferation in certain models. A humanized monoclonal antibody to NRP1 is currently being evaluated as a potential anti‐cancer therapy in clinical trials. However, the expression of NRP1 in cancer and physiological angiogenesis has yet to be systematically described. Here we characterize the in situ expression of NRP1 in human cancer and during mammalian development. A monoclonal antibody to human NRP1 was generated and validated for immunohistochemistry by western blotting, use of formalin‐fixed cell pellets transfected with NRP1, immunofluorescence, and comparison with in situ hybridization. NRP1 expression was assessed in whole sections of 65 primary breast carcinomas, 95 primary colorectal adenocarcinomas, and 90 primary lung carcinomas. An additional 59 human metastases, 16 xenografts, and three genetically engineered mouse tumour models were also evaluated. Immunoreactivity for NRP1 was seen in vessels from normal tissues adjacent to cancer and in 98–100% of carcinomas. Tumour cell expression of NRP1 was also observed in 36% of primary lung carcinomas and 6% of primary breast carcinomas, but no colorectal adenocarcinomas. NRP1 was evaluated in mouse embryos, where expression was limited to the nervous system, endocardium, vascular smooth muscle, and, focally, endothelium on subsets of vessels. Moreover, in a model of VEGF‐dependent angiogenesis in the postnatal mouse trachea, blockade of NRP1 signalling resulted in defective angiogenesis and recapitulated the effects of anti‐VEGF treatment. These observations confirm NRP1 as a valid anti‐angiogenic target in malignancy, and as a potential direct anti‐tumour target in a subset of cancers. The data also confirm a role for NRP1 in physiological, VEGF‐mediated angiogenesis. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finkle, D., Quan, Z. R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W. L., Hollingshead, P., Schwall, R., Koeppen, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0448 · Cited by 125
Self-citation
Cited by
Yunna, C., Mengru, H., Lei, W., & Weidong, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173090 · Cited by 2,454
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
Peach, C. J., Mignone, V. W., Arruda, M. A., Alcobia, D. C., Hill, S. J., Kilpatrick, L. E., & Woolard, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041264 · Cited by 512
Prud’homme, G. J., & Glinka, Y. (2012) · Oncotarget · doi:10.18632/oncotarget.626 · Cited by 275
TGF-β family co-receptor function and signaling
Nickel, J., Ten Dijke, P., & Mueller, T. D. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx126 · Cited by 198
Hota, P. K., & Buck, M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1019-0 · Cited by 170
A7RC peptide modified paclitaxel liposomes dually target breast cancer
Cao, J., Wang, R., Gao, N., Li, M., Tian, X., Yang, W., Ruan, Y., Zhou, C., Wang, G., Liu, X., et al. (2015) · Biomaterials Science · doi:10.1039/c5bm00161g · Cited by 93
Protein kinase LKB1 promotes RAB7-mediated neuropilin-1 degradation to inhibit angiogenesis
Okon, I. S., Coughlan, K. A., Zhang, C., Moriasi, C., Ding, Y., Song, P., Zhang, W., Li, G., & Zou, M.-H. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75371 · Cited by 52
Metadata
- Authors
- Jubb, A. M., Strickland, L. A., Liu, S. D., Mak, J., Schmidt, M., & Koeppen, H.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2011-10-25
- Volume
- 226
- Issue
- 1
- Pages
- 50-60
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2022728604
- Cited by
- 188
- References
- 1
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.